• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai, July 12

The US Food and Drug Administration has approved the Chennai-based Orchid Chemicals & Pharmaceuticals' Abbreviated New Drug Application of Cephalexin oral suspension, according to a press release from Orchid. Cephalexin, an off-patent molecule, is among Orchid's distribution alliance with Par Pharmaceuticals Inc, US. Orchid's Cephalexin capsules are now being marketed in the US in distribution partnership with Par.

Orchid distributes 12 dosage forms, oral solids and injections in the US market including the latest approved suspension, the release said.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Century plans to downsize workforce in Mumbai mill

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line